No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer

被引：60

作者：

Campbell, Ian G.

Eccles, Diana M.

Choong, David Y. H.

机构：

[1] Peter MacCallum Canc Ctr, VBCRC Canc Genet Lab, Ctr Canc Genom & Predict Med, Melbourne, Vic 3002, Australia

[2] Princess Anne Hosp, Wessex Clin Genet Serv, Southampton SO16 5YA, Hants, England

来源：

CANCER LETTERS | 2006年 / 240卷 / 02期

关键词：

MDM2; polymorphism; cancer predisposition; breast cancer; ovarian cancer; case-control study;

D O I：

10.1016/j.canlet.2005.09.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A functional T to G germline polymorphism, in the promoter region of MDM2 (SNP309) has been reported to profoundly accelerate tumor formation suggesting that it may also represent a powerful cancer predisposing allele. To investigate the role of SNP309 in cancer predisposition we undertook a case-control study of this polymorphism among 351 women diagnosed with breast cancer, 302 women diagnosed with ovarian and 258 female controls from a British population. The GG genotype was not associated with either breast cancer (OR 1.04, 95% CI 0.67-1.60) or ovarian cancer (OR 0.86, 95% CI 0.53-1.37). This study has found no evidence that the GG genotype of the MDM2 SNP309 polymorphism is associated with early onset or familial breast cancer or with ovarian cancer. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

引用

页码：195 / 197

页数：3

共 7 条

[1] A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans [J].

Bond, GL ;

Hu, WW ;

Bond, EE ;

Robins, H ;

Lutzker, SG ;

Arva, NC ;

Bargonetti, J ;

Bartel, F ;

Taubert, H ;

Wuerl, P ;

Onel, K ;

Yip, L ;

Hwang, SJ ;

Strong, LC ;

Lozano, G ;

Levine, AJ .

CELL, 2004, 119 (05) :591-602

[2] Abnormal expression of MDM-2 in breast carcinomas [J].

BuesoRamos, CE ;

Manshouri, T ;

Haidar, MA ;

Yang, Y ;

McCown, P ;

Ordonez, N ;

Glassman, A ;

Sneige, N ;

Albitar, M .

BREAST CANCER RESEARCH AND TREATMENT, 1996, 37 (02) :179-188

[3] GENETIC EPIDEMIOLOGY OF EARLY-ONSET BREAST-CANCER [J].

ECCLES, D ;

MARLOW, A ;

ROYLE, G ;

COLLINS, A ;

MORTON, NE .

JOURNAL OF MEDICAL GENETICS, 1994, 31 (12) :944-949

[4] BRCA1 mutations in southern England [J].

Eccles, DM ;

Englefield, P ;

Soulby, MA ;

Campbell, IG .

BRITISH JOURNAL OF CANCER, 1998, 77 (12) :2199-2203

[5] MDM2 OVEREXPRESSION IS RARE IN OVARIAN-CARCINOMA IRRESPECTIVE OF TP53 MUTATION STATUS [J].

FOULKES, WD ;

STAMP, GWH ;

AFZAL, S ;

LALANI, N ;

MCFARLANE, CP ;

TROWSDALE, J ;

CAMPBELL, IG .

BRITISH JOURNAL OF CANCER, 1995, 72 (04) :883-888

[6] Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53 [J].

Lundgren, K ;

Luna, RMDO ;

McNeill, YB ;

Emerick, EP ;

Spencer, B ;

Barfield, CR ;

Lozano, G ;

Rosenberg, MP ;

Finlay, CA .

GENES & DEVELOPMENT, 1997, 11 (06) :714-725

[7] AMPLIFICATION OF A GENE ENCODING A P53-ASSOCIATED PROTEIN IN HUMAN SARCOMAS [J].

OLINER, JD ;

KINZLER, KW ;

MELTZER, PS ;

GEORGE, DL ;

VOGELSTEIN, B .

NATURE, 1992, 358 (6381) :80-83

← 1 →